Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJacqueline S. GarciaPDP DesaiJZJoshua F. Zeidner

Discussion

Loading...

Member takes

Overview

Retrospective cohort review shows venetoclax plus hypomethylating agents improves remission in acute myeloid leukemia, indicating a promising treatment for ineligible patients.

Key Points

  • This study aims to evaluate the effectiveness of venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy.
  • Conducted an international retrospective chart review involving 576 adults across 17 academic sites.
  • Matched 288 venetoclax plus hypomethylating agents patients with controls receiving non-venetoclax regimens based on age and risk factors.
  • Analyzed composite complete remission rates, overall survival, and transfusion independence rates between treatment groups.
  • VEN+HMA patients achieved a 63.7% complete remission rate compared to 46.0% in control patients (p < 0.01).
  • Median overall survival was longer for VEN+HMA patients at 17.4 months (95% CI: 13.3–21.0) versus 13.6 months (95% CI: 10.5–15.9) in controls.
  • Transfusion independence rates were higher in the VEN+HMA group at 63.7% compared to 53.2% in controls.

Cite This Study

Garcia et al. (2026) studied this question.

synapsesocial.com/papers/6a6d97eae258b358b3c6ac99https://doi.org/10.1080/10428194.2026.2696455
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia2024 · 5 citations
  2. 2The Introduction of Hypomethylation Agents and Venetoclax into Standard Care for Older Patients with Acute Myeloid Leukemia: A Retrospective Real-World Analysis of Feasibility, Safety, and Effectiveness from an Outpatient Hematology Center.2026
  3. 3Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  4. 4A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients2024 · 2 citations
  5. 5Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis2025